Table 1 Frequency of clinicopathological characteristics in all breast cancer patients according to p-eIF2α expression.
From: Phosphorylated eIF2α predicts disease-free survival in triple-negative breast cancer patients
Characteristics | n | p-eIF2α | P | |
|---|---|---|---|---|
Low | High | |||
Age (years) | 0.451 | |||
<50 | 87 | 32(36.8%) | 55(63.2%) | |
≥50 | 146 | 61(41.8%) | 85(58.2%) | |
Menopausal status | 0.467 | |||
Pre | 126 | 53(42.1%) | 73(57.9%) | |
Post | 107 | 40(37.4%) | 67(62.6%) | |
Pathological subtype | 0.073 | |||
IDC | 204 | 77(37.7%) | 127(62.3%) | |
Others | 29 | 16(55.2%) | 13(44.8%) | |
Histological grade | 0.425 | |||
Low | 124 | 49(39.5%) | 75(60.5%) | |
High | 86 | 32(37.2%) | 54(62.8%) | |
Unknown | 23 | 12(52.2%) | 11(47.8%) | |
Stage | 0.392 | |||
I and II | 182 | 70(38.5%) | 112(61.5%) | |
III | 51 | 23(45.1%) | 28(54.9%) | |
Tumor size | 0.686 | |||
≤2 cm | 61 | 23(37.7%) | 38(62.3%) | |
2–5 cm | 121 | 47(38.8%) | 74(61.2%) | |
>5 cm | 51 | 23(45.1%) | 28(54.9%) | |
Node status | 0.039 | |||
Negative | 127 | 43(33.9%) | 84(66.1%) | |
Positive | 106 | 50(47.2%) | 56(52.8%) | |
LVI | 0.127 | |||
Negative | 149 | 54(36.2%) | 95(63.8%) | |
Positive | 84 | 39(46.4%) | 45(53.6%) | |
ER status | 0.852 | |||
Negative | 116 | 47(40.5%) | 69(59.5%) | |
Positive | 117 | 46(39.3%) | 71(60.7%) | |
PR status | 0.608 | |||
Negative | 128 | 53(41.4%) | 75(58.6%) | |
Positive | 105 | 40(38.1%) | 65(61.9%) | |
HER-2 status | 0.519 | |||
Negative | 147 | 61(41.5%) | 86(58.5%) | |
Positive | 86 | 32(37.2%) | 54(62.8%) | |
Ki67 status | 0.707 | |||
<20% | 94 | 38(40.4%) | 56(59.6%) | |
≥20% | 80 | 34(42.5%) | 46(57.5%) | |
Unknown | 59 | 21(35.6%) | 38(64.4%) | |
Molecular subtype | 0.458 | |||
Luminal | 84 | 38(45.2%) | 46(54.8%) | |
Her2+ | 86 | 32(37.2%) | 54(62.8%) | |
Triple-negative | 63 | 23(36.5%) | 40(63.5%) | |
Chemotherapy | 0.267 | |||
Doxorubicin based | 124 | 55(44.4%) | 69(55.6%) | |
Taxanes added | 82 | 26(31.7%) | 56(68.3%) | |
CMF or Xeloda | 6 | 2(33.3%) | 4(66.7%) | |
None | 21 | 10(47.6%) | 11(52.4%) | |
Radiotherapy | 0.703 | |||
No | 157 | 64(40.8%) | 93(59.2%) | |
Yes | 76 | 29(38.2%) | 47(61.8%) | |
